A brand-new federal multidistrict litigation docket is now open, and families across the United States are racing to understand their legal rights. On April 2, 2026, the Judicial Panel on Multidistrict Litigation officially created MDL No. 3178, consolidating lawsuits tied to the first-ever botulism outbreak in U.S. history linked to infant formula. If your baby consumed ByHeart Whole Nutrition Infant Formula and became ill, what happens next in this litigation could directly affect your family’s ability to recover compensation.
What Happened: The ByHeart Infant Formula Botulism Outbreak
The crisis began quietly in October 2025 when the California Department of Public Health identified a troubling pattern — three neonates in separate households had all been exposed to the same infant formula brand. That initial cluster triggered a joint investigation by the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration that would ultimately uncover the largest infant formula safety emergency in modern American history.
By November 8–11, 2025, ByHeart issued a full nationwide recall of its Whole Nutrition Infant Formula after federal health agencies formally linked the product to 51 suspected or confirmed infant botulism cases spanning 19 states. The scale of the outbreak is unprecedented. Experts cited in national reporting have confirmed this is the first time a U.S. infant formula has ever been connected to a botulism outbreak — a distinction that makes the ByHeart infant formula lawsuit litigation uniquely significant from both a public health and legal standpoint.
On December 23, 2025, ByHeart’s laboratory partner IEH Laboratories completed testing of 36 finished product samples drawn from two recalled lots. The results were alarming: 6 of those 36 samples tested positive for Clostridium botulinum, the bacterium that produces the toxin responsible for botulism. The confirmed presence of the pathogen in finished product — formula that had already been sold and fed to infants — gave families and their attorneys the kind of direct laboratory evidence that rarely exists this early in mass tort litigation.
When the CDC expanded its case definition on December 10, 2025, investigators extended the lookback window all the way to March 23, 2022 — the date ByHeart formula first became commercially available. That decision suggests that contamination may have been a persistent issue throughout the product’s market life, not an isolated manufacturing anomaly. Families who purchased ByHeart formula as far back as 2022 may have affected children without ever knowing the cause of their infant’s illness.
How Sick Infants Got: Botulism Symptoms and Hospitalizations
Infant botulism is among the most serious foodborne illnesses a newborn can develop. The toxin produced by Clostridium botulinum attacks the nervous system, and in infants — whose immune systems are not yet fully developed — the consequences can be life-altering. Symptoms reported in connection with the ByHeart infant formula lawsuit cases include constipation, progressive muscle weakness, poor feeding, labored breathing, and in severe cases, full paralysis. Many affected infants required prolonged hospitalizations, some spending weeks in intensive care units on mechanical ventilation.
A total of 51 infants were hospitalized across 19 states as of the most recently reported figures. Families who have already filed suit include those from Washington, Arizona, California, and Kentucky. While no deaths have been officially reported in connection with this outbreak, the severity of infant botulism means that some children may face lasting neurological consequences that will require years of medical monitoring and treatment. Families navigating those long-term costs should consider using a personal injury settlement calculator to begin understanding the potential value of their claims.
The recalled formula was widely distributed through major national retailers. ByHeart Whole Nutrition Infant Formula was sold at Amazon, Kroger, Walmart, Whole Foods, Target, and Sam’s Club. That broad retail footprint means affected families span virtually every demographic and geography — a factor the JPML cited in its decision to centralize the litigation nationally.
MDL 3178: What the New Federal Litigation Looks Like
On April 2, 2026, the Judicial Panel on Multidistrict Litigation issued its transfer order officially establishing MDL No. 3178, In re: ByHeart, Inc., Infant Formula Marketing, Sales Practices, and Products Liability Litigation. The case has been assigned to Judge Arun S. Subramanian in the Southern District of New York — the same district where ByHeart is headquartered and where 8 of the 19 consolidated actions were already pending at the time of transfer.
The JPML consolidated actions from 12 different federal districts into a single proceeding. The panel found that the cases share substantial common questions of fact — including questions about ByHeart’s manufacturing processes, quality control procedures, testing protocols, and the timeline of what the company knew and when. The panel further concluded that centralization would prevent duplicative expert discovery and eliminate the risk of inconsistent pretrial rulings across multiple jurisdictions, a standard rationale for MDL formation that carries particular weight in product liability cases involving complex scientific evidence.
Notably, all responding parties — including ByHeart itself — supported MDL centralization. That unusual posture suggests even the defendant recognized that a unified proceeding serves judicial efficiency interests in a case of this complexity. As of the May 2026 JPML statistics report, MDL 3178 is active among 159 total MDL dockets nationwide, which collectively carry 199,684 pending actions.
The 19 consolidated lawsuits break into two distinct categories. Nine are personal injury actions filed on behalf of infants who allegedly became seriously ill with botulism after consuming the formula. The remaining ten are economic-injury class actions filed by purchasers who seek compensation for the cost of the recalled formula and related economic harm, even in cases where the infant did not become symptomatic. Families with injured children face a different legal path than those pursuing economic claims, and the bellwether trial selection process — the next major litigation milestone expected from Judge Subramanian — will likely prioritize the personal injury track.
ByHeart’s Regulatory History: The 2023 FDA Warning Letter
The ByHeart infant formula lawsuit did not emerge in a regulatory vacuum. In 2023, the FDA issued a formal warning letter to ByHeart citing what it described as “significant violations” at the company’s Pennsylvania manufacturing facility. Warning letters of this type are serious enforcement actions that typically follow inspections revealing departures from Good Manufacturing Practice regulations and other federal safety standards.
ByHeart has publicly stated that the Pennsylvania facility identified in the 2023 warning letter was not involved in producing the lots subject to the November 2025 recall. That defense will almost certainly be tested through discovery in MDL 3178. Plaintiffs’ attorneys — including prominent food safety litigator Bill Marler, who represents several affected families and has said ByHeart has “a lot to answer for” — will have broad authority to seek internal documents, communications, and inspection records through the centralized discovery process. Families considering claims against ByHeart for injuries that may constitute medical malpractice calculator-level damages from defective product exposure should document all medical records and formula purchase receipts now.
The regulatory history is significant because it may establish a pattern of notice. If ByHeart received federal warnings about manufacturing deficiencies years before the outbreak and failed to implement adequate corrective measures across its operations, that timeline could support claims for enhanced damages and strengthen the negligence theories at the core of the personal injury litigation.
Key Data: ByHeart Infant Formula Lawsuit and Outbreak Statistics
| Data Point | Detail | Source / Date |
|---|---|---|
| Total hospitalized infants | 51 suspected or confirmed botulism cases | CDC / FDA, November 2025 |
| States affected | 19 states | CDC outbreak investigation, December 2025 |
| Positive lab samples | 6 of 36 finished product samples positive for C. botulinum | IEH Laboratories, December 23, 2025 |
| Recall date | November 8–11, 2025 | ByHeart / FDA recall notice |
| MDL creation date | April 2, 2026 | JPML Transfer Order, MDL No. 3178 |
| Presiding judge | Judge Arun S. Subramanian, S.D.N.Y. | JPML Order, April 2026 |
| Consolidated actions | 19 total (9 personal injury + 10 economic class actions) | JPML Transfer Order, April 2026 |
| Districts of origin | 12 federal districts | JPML Transfer Order, April 2026 |
| Lookback period | Cases from March 23, 2022 onward included | CDC expanded case definition, December 10, 2025 |
| FDA warning letter | Issued 2023 for “significant violations” at PA facility | FDA Warning Letter, 2023 |
What Affected Families Must Do Right Now
If your infant consumed ByHeart Whole Nutrition Infant Formula at any point since the product launched in March 2022, and your baby experienced symptoms consistent with infant botulism — including unexplained constipation, muscle weakness, feeding difficulties, or breathing problems — time is a critical factor. MDL 3178 is newly formed, and the early stages of centralized litigation are when attorneys are most aggressively building plaintiff rosters for bellwether trial selection. Families who document their claims thoroughly and promptly will be best positioned as the litigation moves forward.
Here are the immediate steps every affected family should take in connection with the ByHeart infant formula lawsuit:
- Preserve all physical evidence. Do not discard any remaining formula, packaging, lot numbers, or purchase receipts. Lot numbers are essential for linking your child’s exposure to the recalled batches and to the positive lab samples identified by IEH Laboratories.
- Request complete medical records. Obtain records of every hospitalization, emergency room visit, specialist consultation, and laboratory test related to your infant’s illness. These records form the evidentiary spine of any personal injury claim.
- Document ongoing symptoms and treatment. Infant botulism can have prolonged recovery timelines. Keep a detailed written log of symptoms, medical appointments, therapies, and out-of-pocket costs from this point forward.
- Contact the CDC and FDA. Families who have not yet reported their child’s illness to federal health authorities should do so through the CDC botulism reporting portal. Official case documentation strengthens both the public health record and individual legal claims.
- Consult a mass tort attorney immediately. Statutes of limitations vary by state and can be as short as two years from the date of injury. With MDL 3178 now accepting consolidated cases, retaining qualified legal counsel promptly ensures your family does not miss filing deadlines.
Understanding what your child’s injuries may be worth is an important early step. Families who believe their infant sustained serious neurological harm from Clostridium botulinum exposure may be dealing with damages that extend well beyond initial hospitalization costs. The long-term neurological monitoring and developmental support that some botulism survivors require can represent substantial lifetime expense that must be accurately valued before any settlement is considered.
Frequently Asked Questions About the ByHeart Infant Formula Lawsuit
What is MDL 3178 and how does it affect my family’s ByHeart claim?
MDL No. 3178, created by the JPML on April 2, 2026, is a federal multidistrict litigation proceeding that consolidates all ByHeart infant formula lawsuits filed in federal courts across the country into a single docket before Judge Arun S. Subramanian in the Southern District of New York. Consolidation means your case will be coordinated with 18 other actions for pretrial proceedings including discovery and expert testimony, which eliminates duplicative work and ensures consistent rulings. Your individual claim is not eliminated — personal injury cases are ultimately remanded to their home districts for trial if not resolved through settlement during the MDL process.
My baby had symptoms but was never diagnosed with botulism. Can I still file a ByHeart infant formula lawsuit?
Potentially yes. The CDC expanded its case definition in December 2025 to capture both confirmed and suspected botulism cases, and not all affected infants received a formal botulism diagnosis during their initial hospitalization — particularly those treated in the early months of the outbreak before the formula connection was identified. If your infant consumed ByHeart formula and experienced symptoms such as constipation, muscle weakness, poor feeding, or breathing difficulty, you should preserve all medical records and formula packaging and consult a mass tort attorney to evaluate whether your child’s symptoms fit the clinical profile of infant botulism exposure.
The recalled formula was purchased years ago. Is it too late to file a claim?
It may not be too late, but you should act immediately. The CDC’s expanded case definition extends the outbreak lookback period to March 23, 2022, which means children affected years ago are being included in the investigation. Statutes of limitations in product liability and personal injury cases typically run from the date of injury or the date the injury was discovered — and in cases involving infants, some states apply tolling rules that pause the clock until the child reaches a certain age. Because these deadlines vary significantly by state, the only way to know whether your claim is timely is to consult a qualified attorney as soon as possible.
What compensation could families recover in a ByHeart infant formula lawsuit?
In personal injury cases, damages typically include medical expenses (past and future), hospitalization costs, lost income for caregiving parents, pain and suffering, and in cases involving lasting neurological harm, lifetime care costs and loss of quality of life. Economic class action plaintiffs may recover the purchase price of recalled formula and related out-of-pocket costs. The value of any individual claim depends heavily on the severity of the infant’s illness, the length of hospitalization, the presence of ongoing or permanent symptoms, and the specific facts of the case. With 9 personal injury plaintiffs already consolidated in MDL 3178 and bellwether trials approaching, early claimants may benefit from the precedent-setting outcomes of those trials.
ByHeart says the 2023 FDA warning letter involved a facility unrelated to the recalled formula. Does that hurt the lawsuits?
Not necessarily, and that claim has not yet been tested in litigation. While ByHeart has stated publicly that its Pennsylvania facility — the subject of the 2023 FDA warning letter for “significant violations” — was not involved in producing the recalled lots, plaintiffs’ attorneys will have the opportunity during MDL discovery to demand internal corporate documents, quality control records, and communications that may tell a different story or reveal systemic manufacturing culture issues that transcend individual facilities. The 2023 warning letter remains relevant to establishing notice and a pattern of regulatory non-compliance, which are key elements in products liability claims alleging that ByHeart knew or should have known about contamination risks.
This article is provided for general informational purposes only and does not constitute legal advice; please consult a licensed attorney in your jurisdiction regarding your specific legal situation.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.